



Blockchain Genomics

Introducing 'Colo-Prevent'

The first clinically validated Colorectal Cancer genomic test



Block23.me



About Colo-Prevent

Colo-Prevent is a DNA test that is to be used to identify healthy individuals who have 3-5 fold increased risk of developing colorectal cancer (CRC).

A DNA Saliva Specimen Kit is sent to each individual for genomic analysis. The Colo-Prevent risk score is determined following analysis of the individual's DNA by an algorithm programmed into encrypted software generating a patient report of relative lifetime risk of developing CRC, including clinical advice on how to manage this, returned to each individual and their GP.


Colo-Prevent testing will improve overall CRC survival statistics, as there is strong evidence to suggest that screened tumours are detected at an earlier, more curable stage which in turn will deliver economic savings to the healthcare system.



Why Colo-Prevent

Block23 has identified an algorithm of highly validated SNPs associated with an increased lifetime risk of CRC. The SNPs were identified from the largest world Genome Wide Association Study of 48,576 European subjects (26,660 CRC cases and 21,916 cancer free controls) in the world.

The Colo-Prevent algorithm takes into account specific alleles to categorise individuals of up to >3-fold increased risk of developing CRC.






Colo-Prevent risk map

Colo-Prevent maps genomic predisposition to a person's lifestyle habits to calculate a composite risk factor, with damaged SNPs being the highest risk factor.


As a result, Colo-Prevent acts as a guideline for individuals to manage their health risks based on the genomic assessment.

This provides doctors and health practitioners valuable information for scheduling more regular screening such as fecal occult blood testing (FOBT) and colonoscopy, as well as recommendations on lifestyle changes.





Block23 AI and Deep Learning monitors Health behaviour changes to deliver actionable data



Block23's Predict platform enables pro-active cancer screening, commencing with colon cancer

If all EU citizens were screened at Stage 1 (or earlier);

- €4bn would be saved from health economies each year
- Saving the lives of 110,000 people*

* EuropaColon, ESO Observatory
ESMO GI June 2018





Colo-Prevent Summary

- available starting August 1, 2018
- First colorectal cancer screen (CRC), clinically validated on over 42,000 cancer patients
- Uses saliva collection kit and AI-powered extended gene analysis for pro-active colon cancer screening
- Blockchain App for data privacy and receiving personalised support
- Intellectual Property under development - incorporates screening and pro-active intervention
- Clinical trials with Oxford University: 42,013 subjects





Colo-Prevent Summary

CRC Pro-active screening to identify and support people at risk of colon cancer

- CRC Colo-Predict screening test
 - Personalised risk of developing colorectal cancer (CRC)
 - Allows lifestyle adaptation and more intensive surveillance
- Facilitates improved screening strategies
 - Screening shifts detection to Stages 1 and 2
 - Dramatically improves patient survival
 - Reduces treatment costs
- Enables personalised, proactive health and wellbeing
 - Genetic risk of developing CRC
 - Individuals at higher risk;
 - Follow-up screening pathways
 - App-based interface to expert support
 - Personalised lifestyle guidance



Find out more about the Block23 project

Website: www.block23.me

Email: info@block23.me